Literature DB >> 7888093

Evolution of nerve fiber degeneration in the striatum in the MPTP-treated squirrel monkey.

L S Forno1, L E DeLanney, I Irwin, J W Langston.   

Abstract

We have examined the ultrastructure of the striatum in squirrel monkeys 1-5 d after a single sc injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 2.5 mg/kg. One untreated monkey served as control. We expected to find a dense degeneration of the dopamine terminals, but found instead that the main abnormality consisted of a focal vacuolation of the tissue, perhaps related to the striosome/matrix mosaic of the neostriatum. The vacuolation involved not only terminals, but also other parts of the neuropil. The severity of the destructive process increased from d 1-5. We conclude that MPP+, the toxic metabolite of MPTP, may gain access to the neuropil, either before or after its active uptake into and subsequent destruction of the dopamine terminals. In the present study, abnormalities were observed simultaneously in the striatum and substantia nigra as early as 24 h after MPTP administration. It is, however, possible that the time-course might differ between the two locations with even shorter time intervals or changes in dosage of MPTP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888093     DOI: 10.1007/BF02816116

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  15 in total

1.  Mitochondria covered with a net of parallel and latticed filaments in nigral neurons of monkeys with experimental parkinsonism.

Authors:  H Nakamura; S Kato; J Tanaka
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 2.  MPTP: current concepts and controversies.

Authors:  J W Langston; I Irwin
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

3.  The acute histopathology of MPTP in the mouse CNS.

Authors:  J D Adams; P W Kalivas; C A Miller
Journal:  Brain Res Bull       Date:  1989 Jul-Aug       Impact factor: 4.077

4.  Effects of MPTP on the fine structure of neurons in substantia nigra of dogs.

Authors:  S C Rapisardi; V O Warrington; J S Wilson
Journal:  Brain Res       Date:  1990-03-26       Impact factor: 3.252

5.  Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum.

Authors:  R J Ferrante; N W Kowall
Journal:  Brain Res       Date:  1987-07-21       Impact factor: 3.252

6.  The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.

Authors:  I Irwin; L E DeLanney; L S Forno; K T Finnegan; D A Di Monte; J W Langston
Journal:  Brain Res       Date:  1990-10-29       Impact factor: 3.252

7.  Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.

Authors:  J C Linder; H Klemfuss; P M Groves
Journal:  Neurosci Lett       Date:  1987-11-23       Impact factor: 3.046

8.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+.

Authors:  B R Ransom; D M Kunis; I Irwin; J W Langston
Journal:  Neurosci Lett       Date:  1987-04-10       Impact factor: 3.046

9.  Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.

Authors:  G A Ricaurte; J W Langston; L E Delanney; I Irwin; S J Peroutka; L S Forno
Journal:  Brain Res       Date:  1986-06-18       Impact factor: 3.252

10.  Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.

Authors:  J Tanaka; H Nakamura; S Honda; K Takada; S Kato
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

View more
  1 in total

1.  Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.

Authors:  Alison L McCormack; Sally K Mak; Maryam Shenasa; William J Langston; Lysia S Forno; Donato A Di Monte
Journal:  J Neuropathol Exp Neurol       Date:  2008-08       Impact factor: 3.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.